Updated / Thursday, 6 Aug 2026 14:49
Shares in nutrition supplement maker Glanbia jumped 8% in Dublin trade this morning after it reported higher revenues and profits for the six months to the end of June and said it was upgrading its full year guidance.
Glanbia’s half year revenues rose by 7% to $2.1 billion from $1.9 billion the same time last year, while group pre-exceptional profit after tax jumped by 34.4% to $175.4m from $132m on a constant currency basis.
EBITDA for the six month period rose by 14.1% to $275.4m from $241.3m the same time last year.
Glanbia also reported adjusted earnings per share of 81.24 US cents, an increase of 30% on the 63.03 US cents reported in 2025.
The board is recommending an interim dividend of 18.92 cent per share, a 10% increase on the previous year’s interim dividend of 17.20 cent.
Hugh McGuire, Glanbia’s chief executive, said the group delivered a strong performance in the first half of the year with adjusted EPS of 81.24 cent, resulting in an upgrade to the company’s guidance for the full year to 17% to 20% growth in adjusted EPS.
The CEO said the company delivered volume and like-for-like revenue growth across all three of its segments – Performance Nutrition, Health & Nutrition and Dairy Nutrition.
He said this reflected “disciplined execution” as it continues to navigate whey cost inflation within the Performance Nutrition division.
“Optimum Nutrition delivered double digit volume growth in the period driven by accelerating category growth, increased distribution, ongoing innovation and the brand’s continued leadership within the category,” Hugh McGuire said.
“We also generated strong volume growth across Health & Nutrition and Dairy Nutrition, with good demand in H&N’s end-use markets and strong volume and pricing growth in protein solutions within DN,” he added.
The CEO said the company continued to advance its group-wide transformation programme, and following strong progress year-to-date, was now increasing its annual cost savings target from $60m to $70m by 2027.
“As a protein powerhouse at the heart of better nutrition, Glanbia is uniquely positioned to meet the growing demand for nutrition that supports healthier and more active lives,” the CEO said.
“We now expect adjusted EPS growth of 17% to 20% which will be driven by category and end-use consumer market demand and a strong operating performance across all three segments,” he added.
Breaking down its divisions, Glanbia said that revenue at its Performance Nutrition unit rose by 6.7% – on a constant currency basis – to $917.2m from $850m, while EBITDA was up 74% to $115.2m from $108.2m.
Glanbia noted that inflation in whey input costs was largely offset by pricing actions, cost savings from the group-wide transformation programme and accretion relating to disposals of non-core brands.
Revenues at its Health & Nutrition division grew by 15.6% to $368.5m from $313m, while EBITDA rose by 9.5% to $68.9m from $60.9m.
Glanbia said the integration of both Sweetmix and Scicore, acquired last August and January 2026 respectively, is progressing well. Capacity expansion projects in the US, Europe and China, underpinned by strong customer demand, also remain on schedule, it added.
Meanwhile, revenue at its Dairy Nutition division moved 3.8% higher to $793.7m from $763.7m while EBITDA jumped 28% to $92.3m from $72.2m the same time last year.
It noted that protein solutions saw double digit volume and pricing growth, supported by favourable consumer trends, particularly in the high-protein ready-to-eat and healthy snacking categories.
Shares in the company moved higher in Dublin trade today.
